Alloy Therapeutics Inc., a biotechnology firm focused on broadening access to drug discovery technologies, has acquired Spannerwerks LLC, a Seattle-based consultancy that advises biopharmaceutical companies on product development and commercialization. Under the terms of the deal, Spannerwerks will operate as a wholly owned subsidiary of Alloy and retain its name. Dara Lockert, Spannerwerks’ chief executive, will join Alloy full-time and continue to lead the team as part of the company’s exec...